Literature DB >> 19208358

A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.

Raffaella Romeo1, Ersilio Del Ninno, Mariagrazia Rumi, Antonio Russo, Angelo Sangiovanni, Roberto de Franchis, Guido Ronchi, Massimo Colombo.   

Abstract

BACKGROUND & AIMS: Chronic infection with hepatitis Delta virus (HDV) is a risk factor for cirrhosis and hepatocellular carcinoma (HCC); predictors of disease outcome are, however, poorly defined. We tracked the course of HDV infection in 299 patients over a mean period of 233 months.
METHODS: We analyzed data from patients who had been HDV positive for at least 6 months (230 males; mean age, 30 years) admitted from 1978 to 2006 to Maggiore Hospital, Milan. HDV infection was defined by the presence of HDV antigen in liver tissue or serum HDV RNA in anti-HDV/hepatitis B surface antigen seropositive patients. At enrollment, 7 patients had acute hepatitis, 101 had mild-moderate chronic hepatitis, 76 had severe chronic hepatitis, and 104 had histologic or clinical cirrhosis. Ninety patients were treated with interferon, 62 with corticosteroids, and 12 with nucleoside analogues; 135 received no therapy.
RESULTS: Over a mean period of 233 months, 82 patients developed cirrhosis. Among the 186 total patients with cirrhosis, 46 developed HCC, 43 ascites, 44 jaundice, and 1 encephalopathy. Female sex, alcohol abuse, and HDV replication were associated with liver decompensation; HBV replication and interferon were associated with HCC development. By the end of the study, 186 patients were still alive, 63 had died, and 29 had received liver transplants. The main cause of death was liver failure (n = 37, 59%); HDV replication was the only independent predictor of mortality.
CONCLUSIONS: Persistent HDV replication leads to cirrhosis and HCC at annual rates of 4% and 2.8%, respectively, and is the only predictor of liver-related mortality.

Entities:  

Mesh:

Year:  2009        PMID: 19208358     DOI: 10.1053/j.gastro.2009.01.052

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  80 in total

1.  Current concept in the pathophysiology of hepatitis delta infection.

Authors:  Grazia Anna Niro; Antonina Smedile
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

Review 2.  HBV/HDV Coinfection: A Challenge for Therapeutics.

Authors:  Christopher Koh; Ben L Da; Jeffrey S Glenn
Journal:  Clin Liver Dis       Date:  2019-05-24       Impact factor: 6.126

Review 3.  [Sexually transmissible hepatitis viruses].

Authors:  S Schaefer
Journal:  Hautarzt       Date:  2009-06       Impact factor: 0.751

4.  Molecular Signature and Mechanisms of Hepatitis D Virus-Associated Hepatocellular Carcinoma.

Authors:  Giacomo Diaz; Ronald E Engle; Ashley Tice; Marta Melis; Stephanie Montenegro; Jaime Rodriguez-Canales; Jeffrey Hanson; Michael R Emmert-Buck; Kevin W Bock; Ian N Moore; Fausto Zamboni; Sugantha Govindarajan; David E Kleiner; Patrizia Farci
Journal:  Mol Cancer Res       Date:  2018-06-01       Impact factor: 5.852

Review 5.  Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.

Authors:  Nicole D Ferrante; Vincent Lo Re
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

6.  Molecular and clinical aspects of hepatitis D virus infections.

Authors:  Elham Shirvani Dastgerdi; Ulf Herbers; Frank Tacke
Journal:  World J Virol       Date:  2012-06-12

7.  Long-term therapy of chronic delta hepatitis with peginterferon alfa.

Authors:  T Heller; Y Rotman; C Koh; S Clark; V Haynes-Williams; R Chang; R McBurney; P Schmid; J Albrecht; D E Kleiner; M G Ghany; T J Liang; J H Hoofnagle
Journal:  Aliment Pharmacol Ther       Date:  2014-05-11       Impact factor: 8.171

Review 8.  Hepatitis D and hepatocellular carcinoma.

Authors:  Zaigham Abbas; Minaam Abbas; Sarim Abbas; Lubna Shazi
Journal:  World J Hepatol       Date:  2015-04-18

9.  Treatment options for hepatitis delta virus infection.

Authors:  Benjamin Heidrich; Michael P Manns; Heiner Wedemeyer
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

Review 10.  Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.

Authors:  Heiner Wedemeyer; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.